| Pralsetinib studied in …STUDIED_INderived15 of 15show fewer |
|---|
| → studied in | NCT04302025Phase 2 · recruiting A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) · 15 trials list this drug (8 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04589845Phase 2 · active not recruiting Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study · 15 trials list this drug (8 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07704658Phase 4 · recruiting Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors · 15 trials list this drug (8 active) | — | — | Lung Non-Small Cell Carcinoma,Malignant Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05525858recruiting KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II · 15 trials list this drug (8 active) | — | — | Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563999Phase 2 · recruiting Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. · 15 trials list this drug (8 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04222972Phase 3 · terminated A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) · 15 trials list this drug (8 active) | — | — | Neoplasm,Neoplasm by Site,Head and Neck Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07418879NA · not yet recruiting A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC · 15 trials list this drug (8 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07010393Phase 4 · not yet recruiting Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study · 15 trials list this drug (8 active) | — | — | Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03037385Phase 1/Phase 2 · completed Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors · 15 trials list this drug (8 active) | — | — | Neoplasm,Neoplasm by Site,Digestive System Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04632992Phase 2 · completed A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response · 15 trials list this drug (8 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06482086Phase 2 · recruiting Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer · 15 trials list this drug (8 active) | — | — | Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04760288Phase 3 · withdrawn A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). · 15 trials list this drug (8 active) | — | — | Thyroid Gland Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04591431Phase 2 · unknown The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy · 15 trials list this drug (8 active) | — | — | Malignant Breast Neoplasm,Malignant Digestive System Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04204928approved for marketing Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC · 15 trials list this drug (8 active) | — | — | Lung Non-Small Cell Carcinoma,Thyroid Gland Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03267940Phase 1 · terminated Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma · 15 trials list this drug (8 active) | — | — | Intrahepatic Cholangiocarcinoma,Cholangiocarcinoma,Extrahepatic Cholangiocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |